scPharmaceuticals Inc.

SCPH

Explore Our Financial Data > Companies > scPharmaceuticals Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	SCPH
CIK	0001604950
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA, 01803
Website	scpharmaceuticals.com
Phone	617-517-0730
CEO	John H. Tucker
Employees	30

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$49.97 million
Pre-Tax Income	$-89.93 million
Net Income	$-91.72 million
Net Income to Common	$-91.72 million
EPS	$-1.82

View All

Balance Sheet

Cash	$40.81 million
Assets	$80.26 million
Liabilities	$101.57 million
Common Equity	$-21.32 million
Liabilities & Equity	$80.26 million

View All

Cash Flow Statement

Net Income	$-91.72 million
Cash From Operating Activities	$-65.86 million
Cash From Investing Activities	$-21,000.00
Cash From Financing Activities	$68.19 million
Change in Cash	$2.30 million

View All

Calculations

NOPAT	$-46.58 million
EBITDA	$-73.86 million
Price to Earnings	N/A
Price to Book	N/A
ROE	1520.24%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s commercial an

Article Link

Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls

Article Link

BC-Most Active Stocks

Raytech Holding Ltd. 7,684,603 2.45

Article Link

MannKind to Acquire scPharmaceuticals for Up to $360 Million

MannKind (MNKD) said Monday it has agreed to acquire scPharmaceuticals (SCPH) for a total deal value

Article Link

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals’ 90 trading d

Article Link